CVS Health (CVS) It is one of the largest healthcare companies in the country, with a vertically integrated business that obtained more than $ 124 million in last year’s income.
But not all parts of your business are the same. The front-end of its CVS retail pharmacies, the brand that is best known, has been struggling for years, just like its colleagues in the sector. The Profit Manager of the Caremark Pharmacy is the goal of political pressure. Aetna’s insurance plans have been successful over the years. And there are questions about the CVS’s ability to succeed in the space of the health provider with his acquisition of Oak Street 2023.
After the ex -Chief Executive Karen Lynch left at the end of last year and the company began a strategic review to break some units, new CEO David Joyner faces answering the question: What is CVS exactly?
It is a retail pharmacy giant, an insurance giant, or is still, as Unitedhealth Group, an uncomfortable mix of vertically integrated parts that, thanks to government rules and regulations, can never completely synchronize its operations?
“We are, as a management team, working on the same question,” Joyner told Yahoo Finance in an interview this week.
But it does not appear that the company is willing to spill any of its parts, As had been reported By the end of last year.
“ I would say the general issue is that I want to turn me into the most entrusted healthcare company in the United States. And to do it, I think we must be in both the supplier’s business, which is in the pharmacy and in the clinic’s business, and I also think we need to be able to manage the risk, which is part of what Aetna and Camerk contributes to the table, ” said Joyner.
“I would expect, by the end of the year, we will have a much better and more organized story to tell,” he added.
One of the main plays that the company made this week was to face the high cost of the popular medicines for GLP-1 weight loss.
CVS chose the Novo Nordisk (Ob) Wegovy as the favorite drug of his form and excluded Eli Lilly (LY) Zepbound on the list. In response, Eli Lilly’s CEO told Yahoo Finance that he was not interested in exclusive offers and was confident at the company’s access points, including online prescription options connected through Lillydirect.
In fact, director David Ricks, the new recipes that are filled for roads instead of Lillydirect injectables, were also equivalent to the total of new recipes for Wegovy.
“I think we really found an interesting part of the market here,” said Ricks, who added that he hopes that there will finally be more weight loss -loss drug insurance coverage.
When asked about this idea, Joyner told Yahoo Finance that he accepts that there is a case to do for online platforms when insurance does not cover products.
“I agree with what Dave Ricks said. I think in these hair loss products, Ed (Erectile Dysfunction), all these other categories that are generally not covered by plan sponsors, there are several ways to access it,” Joyner said.
His own experience, however, informs Joyner after three decades that customers value the experiences of the store in person.
“Although it has always been a profitable distribution point, it has not been the consumer’s preference and even during Covid, (when) people did not leave their homes, we must have seen this massive increase in home delivery. We have not yet approached the optimum rates,” said Joyner.
Joyner added that over time, digital delivery and home delivery numbers may grow.
CVS also announced this week that he left the Affordable Law Law Market, for the second time.
Joyner said his Aetna insurance plans are not profitable and that they are not worth it. If they decided to re -enter the exchange, most states order a five -year waiting period.
“That is why it has been … a decision so important to us, if we could really find our way of profitability before five years, or we should go out. So this tells you the calculation we were looking at in terms of this market,” Joyner said.
He added that there is likely to be more volatility in the ACA space, as questions turn to the future of government -funded subsidies, which are Willing to expire at the end of this yearExcept for new legislation and how it affects the registration rate of the Plan in the coming years.
“I think the ACA business is a viable product as long as it is funded and supported by the Government. I think it is a business that … It can work. Unfortunately, the way we created our product and how our network met and the way we are little, we are subscale and we have not prioritized this segment of our business,” said Joyner.
The company has been trapped in what Joyner called a “bad subscription cycle” with a confluence of factors that include the ways in which the market plans are sold, how the runners and the outputs of other companies are paid, which led to “a really bad mix in the markets that we are serving”.
Since it is a government -subsidized product, it does not follow the data cycles as the normal insurance products do, giving the company a vision and a prediction of certain markets.
Joyner said that the company focuses intensely on its strategic change and felt that the market was not a priority.
“It is not an indictment on the product (O) the market. It is basically our inability to compete effectively,” he said.
“I just didn’t think he had enough time and enough money, frankly, to take us to a path where … it worked for us.”
Stockstory aims to help individual investors overcome the market.
Anjalee Kachmli He is the Yahoo Finance Senior Health Reporter, who covers all the things Pharma, Insurance, Care Services, Digital Health, PBMS and Health Policy and Politics. This includes GLP-1s, of course. Follow Anjalee as anjkhem on social networking platforms X, Linkedin and Bluesky @Anjkhem.
